Neurocrine Biosciences (NASDAQ:NBIX) Given New $204.00 Price Target at Needham & Company LLC

Neurocrine Biosciences (NASDAQ:NBIX) had its price target upped by Needham & Company LLC from $200.00 to $204.00 in a report issued on Friday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other brokerages have also commented on NBIX. Guggenheim raised their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. HC Wainwright boosted their price target on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Morgan Stanley raised their price objective on Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada lifted their target price on Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $199.64.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $166.80 on Friday. The firm has a market capitalization of $16.77 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 0.78 and a beta of 0.39. Neurocrine Biosciences has a 1-year low of $122.14 and a 1-year high of $186.12. The company has a 50-day moving average of $167.81 and a 200 day moving average of $146.40.

Insider Activity at Neurocrine Biosciences

In other news, insider Julie Cooke sold 36,937 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total value of $5,770,298.14. Following the completion of the sale, the insider owned 22,374 shares in the company, valued at approximately $3,495,266.28. The trade was a 62.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the sale, the director directly owned 34,480 shares of the company’s stock, valued at $5,435,772. The trade was a 30.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 395,422 shares of company stock worth $62,448,693 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Several institutional investors have recently bought and sold shares of NBIX. Generali Investments Management Co LLC raised its stake in Neurocrine Biosciences by 19.8% in the second quarter. Generali Investments Management Co LLC now owns 10,644 shares of the company’s stock worth $1,794,000 after buying an additional 1,762 shares in the last quarter. Handelsbanken Fonder AB boosted its position in Neurocrine Biosciences by 9.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 205,871 shares of the company’s stock valued at $34,696,000 after acquiring an additional 18,004 shares in the last quarter. Fulton Bank N.A. boosted its position in Neurocrine Biosciences by 5.2% during the 2nd quarter. Fulton Bank N.A. now owns 4,895 shares of the company’s stock valued at $825,000 after acquiring an additional 243 shares in the last quarter. Valeo Financial Advisors LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $283,000. Finally, Trust Point Inc. purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $245,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
• Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
• Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.